The Lung Cancer Diagnostic And Screening Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
The size of the Lung Cancer Diagnostic And Screening Global Market Report 2024 has seen steady growth in recent years. The market size is projected to increase from $2.34 billion in 2024 to $2.56 billion in 2025, with a compound annual growth rate (CAGR) of 9.6%.
The Lung Cancer Diagnostic And Screening Global Market Report 2024 predicts that by 2029 the market size will expand to $3.69 billion, with a compound annual growth rate (CAGR) of 9.5%.
Download Your Free Sample of the 2025 Lung Cancer Diagnostic And Screening Market Report and Uncover Key Trends Now!The key drivers in the lung cancer diagnostic and screening market are:
• Rising incidence of lung cancer
• Greater focus on early detection of the disease
• Expansion of high-risk screening programs and shifts towards personalized medicine
• Government initiatives and funding supporting lung cancer detection and treatment programs
The lung cancer diagnostic and screening market covered in this report is segmented –
1) By Product: Instruments, Consumables And Accessories
2) By Test: Biomarkers Tests, Imaging Test, Biopsy, Blood Test, Other Tests
3) By Cancer Type: Non-Small Cell Lung Cancer, Small Cell Lung Cancer
4) By End User: Hospital, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, Other End-Users
The key trends in the lung cancer diagnostic and screening market are:
• The emergence of novel screening modalities is shaping the future of the market.
• The market will be significantly influenced by advancements in biomarker testing.
• Integration of artificial intelligence (AI) in lung cancer diagnostic and screening procedures is an emerging trend.
• The growing focus on early stage detection and expansion of low-dose CT screening programs is also a key upcoming trend.
The major players in the lung cancer diagnostic and screening market are:
• Pfizer Inc
North America was the largest region in the lung cancer diagnostic and screening market in 2024